LARVOL is pleased to present a moderated discussion with top oncologists following ASCO's Annual Meeting 2021. In the video below, Dr. Kevin Knopf, Dr. Aaron Goodman, and Dr. Jordan Gauthier discuss the practice-changing impact of ASCO presentations in DLBCL.
On June 7, 2021, LARVOL hosted an Oncology Panel to discuss the top diffuse large B-cell lymphoma (DLBCL) clinical trial abstracts presented during the American Society of Clinical Oncology (ASCO) Annual Meeting 2021, held on June 4-8, 2021. Dr. Kevin Knopf from the University of California, San Francisco moderated the discussion between hematology KOLs Dr. Aaron Goodman from the University of California, San Diego and Dr. Jordan Gauthier from Fred Hutchinson Cancer Center.
The discussion covered ASCO abstract #7513 Long-term analyses from L-MIND, a phase II study of tafasitamab (MOR208) combined with lenalidomide (LEN) in patients with relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL), ASCO abstract #7540: First-MIND: A phase Ib, open-label, randomized study to assess safety of tafasitamab (tafa) or tafa + lenalidomide (LEN) in addition to R‑CHOP in patients with newly diagnosed DLBCL, and ASCO abstract #7512 Polatuzumab vedotin (Pola) + rituximab (R) + lenalidomide (Len) in patients (pts) with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL): Primary analysis of a phase 1b/2 trial.
Watch this video for the full discussion:
Our ASCO Panel Series covered six therapeutic areas including DLBCL. Click below to read more about them and watch their video analysis.
In this edition of our ongoing series "In The Spotlight", we're excited to chat with Linh Nguyen, the VP Sales at LARVOL. With a passion for healthcare and a commitment to making a difference in the oncology field, Linh has been a vital part of our team for over six years. Let’s get to know Linh better through her own words, exploring her journey, motivations, and the personal interests that round out her life.
In 2020, as most of the business world wrestled with the transition to remote work, my company chose an alternate approach. As Founder and CEO, I began pushing for a very different but equally culture-shifting change. I moved our corporate headquarters to the metaverse, and we’re never looking back.
The battle against cancer is shifting, with Antibody-Drug Conjugates (ADCs) leading a revolution in precision therapy. These biological innovators are changing the game for many patients, offering a glimmer of hope in an often daunting prognosis. Here’s a closer look at the promising world of ADCs and how they're transforming cancer care.
Navigating the busy world of pharmaceutical conferences can be a daunting task, filled with endless sessions, abstracts, and updates to keep track of. This is where LARVOL CONF comes into play – offering a simple, yet powerful way to organize and manage conference information effectively.